Does rivaroxaban 10 mg daily improve outcomes compared to an antiplatelet-based strategy in patients without an established indication for oral anticoagulation after successful TAVR?
Routine use of rivaroxaban 10 mg daily after successful TAVR in patients without an indication for oral anticoagulation is harmful, increasing both thromboembolic/mortality risks and bleeding.
In patients without an established indication for oral anticoagulation after successful TAVR, a treatment strategy including rivaroxaban at a dose of 10 mg daily was associated with a higher risk of death or thromboembolic complications and a higher risk of bleeding than an antiplatelet-based strategy. (Funded by Bayer and Janssen Pharmaceuticals; GALILEO ClinicalTrials.gov number, NCT02556203.).
Dangas et al. (Sat,) studied this question.